Century Therapeutics, Inc.
General ticker "IPSC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $55.8M (TTM average)
Century Therapeutics, Inc. follows the US Stock Market performance with the rate: 29.2%.
Estimated limits based on current volatility of 14.3%: low 1.95$, high 2.41$
Factors to consider:
- Total employees count: 165 (-10.3%) as of 2023
- Top business risk factors: Limited operating history, Operational and conduct risks, Dependence on product candidates, Technological challenges, Gene editing technology risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.89$, 2.63$]
- 2025-12-31 to 2026-12-31 estimated range: [0.95$, 2.68$]
Financial Metrics affecting the IPSC estimates:
- Positive: with PPE of -0.6 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -134.50 <= 0
- Positive: 42.77 < Shareholder equity ratio, % of 45.68 <= 64.37
- Positive: Investing cash flow per share per price, % of 57.99 > -0.63
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of -28.14 <= -0.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term IPSC quotes
Long-term IPSC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $5.20MM | $2.23MM | $6.59MM |
| Operating Expenses | $139.03MM | $148.78MM | $144.73MM |
| Operating Income | $-133.83MM | $-146.55MM | $-138.14MM |
| Non-Operating Income | $2.99MM | $11.75MM | $13.36MM |
| Interest Expense | $0.00MM | $0.54MM | $0.00MM |
| R&D Expense | $107.17MM | $97.71MM | $107.24MM |
| Income(Loss) | $-130.84MM | $-134.79MM | $-124.78MM |
| Taxes | $0.09MM | $1.88MM | $1.79MM |
| Profit(Loss)* | $-130.93MM | $-136.67MM | $-126.57MM |
| Stockholders Equity | $302.74MM | $184.75MM | $161.36MM |
| Assets | $486.54MM | $360.69MM | $353.22MM |
| Operating Cash Flow | $14.05MM | $-88.35MM | $-110.14MM |
| Capital expenditure | $30.60MM | $13.74MM | $0.15MM |
| Investing Cash Flow | $-13.13MM | $61.13MM | $47.48MM |
| Financing Cash Flow | $27.16MM | $-9.72MM | $74.56MM |
| Earnings Per Share** | $-2.27 | $-2.30 | $-1.61 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.